Bristol Myers Squibb (CELG-RI) Share-based Compensation (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Share-based Compensation of $135.0 million for Q2 2026, down 1.46% year-over-year from $137.0 million in Q2 2025, and down 7.53% quarter-over-quarter from $146.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Share-based Compensation (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Share-based Compensation for 18 consecutive years, with $135.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation fell 1.46% year-over-year to $135.0 million; the TTM figure through Jun 2026 stood at $553.0 million (up 4.34% YoY), while the FY2025 annual figure was $553.0 million, up 9.07% from the prior year.
- Share-based Compensation slipped to $135.0 million in Q2 2026 per CELG-RI's latest filing, from $146.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $146.0 million in Q1 2026 and bottomed at $107.0 million in Q1 2022.
- Historically, Share-based Compensation has averaged $128.7 million across 5 years, with a median of $130.5 million in 2023.
- Annual changes were most pronounced in 2022 — Share-based Compensation fell 29.14% — and 2023, when it advanced 18.1%.
- Bristol Myers Squibb's Share-based Compensation stood at $119.0 million in 2022, then climbed by 6.72% to $127.0 million in 2023, then fell by 5.51% to $120.0 million in 2024, then rose by 10.83% to $133.0 million in 2025, then advanced by 1.5% to $135.0 million in 2026.
- Business Quant data shows CELG-RI's Share-based Compensation at $135.0 million in Q2 2026, $146.0 million in Q1 2026, and $133.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.15 Bn | 634.39 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 469.47 Bn | 462.91 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 380.63 Bn | 373.49 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 302.58 Bn | 294.89 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.84 Bn | 252.94 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.70 Bn | 222.71 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 182.92 Bn | 179.74 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 161.16 Bn | 149.47 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 105.59 Bn | 101.42 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 135.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 135.00 Mn |
| Jun 30, 2026 | 135.00 Mn |
| Mar 31, 2026 | 146.00 Mn |
| Mar 31, 2026 | 146.00 Mn |
| Dec 31, 2025 | 133.00 Mn |
| Dec 31, 2025 | 133.00 Mn |
| Sep 30, 2025 | 139.00 Mn |
| Sep 30, 2025 | 139.00 Mn |
| Jun 30, 2025 | 137.00 Mn |
| Jun 30, 2025 | 137.00 Mn |
| Mar 31, 2025 | 144.00 Mn |
| Mar 31, 2025 | 144.00 Mn |
| Dec 31, 2024 | 120.00 Mn |
| Dec 31, 2024 | 120.00 Mn |
| Sep 30, 2024 | 129.00 Mn |
| Sep 30, 2024 | 129.00 Mn |
| Jun 30, 2024 | 125.00 Mn |
| Jun 30, 2024 | 125.00 Mn |
| Mar 31, 2024 | 133.00 Mn |
| Mar 31, 2024 | 133.00 Mn |